C12-iE-DAP
Based on 1 publication(s) in Google Scholar
C12-iE-DAP (Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid) is a highly potent and selective NOD1 agonist, with an EC50 of 0.027 nM in HEK-Blue cells expressing human NOD1. C12-iE-DAP activates the NOD1/RIPK2 signaling pathway and its downstream p38 MAPK and NF-κB, induces the expression of inflammatory mediators such as IL6 and IL8, and exerts synergistic effects with TLR4, Dectin-1 or Mincle signaling. C12-iE-DAP can be used in studies related to vascular inflammation, tumor metastasis and neuroinflammation.
For research use only. We do not sell to patients.
- CAS No.: 1269619-57-9
- Formula: C24H43N3O8
- Molecular Weight:501.61
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) C12-iE-DAP
More
Biological Activity
Description
IC50 & Target
[1]|
hNOD1 0.027 nM (EC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | EC50 |
0.027 nM
Compound: 16
|
Agonist activity at human NOD-1 expressed in human HEK293 cells assessed as NF-kappaB induction by spectrophotometric analysis
Agonist activity at human NOD-1 expressed in human HEK293 cells assessed as NF-kappaB induction by spectrophotometric analysis
|
[PMID: 21299227] |
In Vitro
C12-iE-DAP (compound 16) (Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid) induces NF-κB/AP-1-dependent SEAP signaling in HEK-Blue cells expressing human NOD1, with an EC50 of 0.027 nM[5].
C12-iE-DAP (0.01-10 μg/mL; 18 h) acts synergistically with Curdlan (HY-131166) or TDB to enhance NF-κB/AP-1-dependent SEAP expression in the human monocytic cell line THP1-XBlue-CD14, with activity levels exceeding the additive effect of stimulation by each agonist alone[2].
C12-iE-DAP (1-100 μg/mL; 24 h) acts synergistically with Curdlan or TDB to enhance the production of the IL-8 cytokine in the human monocyte cell line THP-1, with the production level exceeding the additive effect of stimulation by individual agonists[2].
C12-iE-DAP (10-9-10-8 M; 1 h) upregulates CD11b in granulocytes from fresh human whole blood in a dose-dependent manner, with a stronger induction effect at 10-8 M than at 10-9 M; whereas compound 27 exhibits stronger activity at both of the above concentrations[5].
C12-iE-DAP (5 μg/mL; 6 h) induces IL6 and IL8 mRNA expression in primary human brain pericytes and increases IL-8 release in cell culture supernatants[1].
C12-iE-DAP (1 μg/mL; 6 h)-induced IL8 expression in human brain pericytes depends on the NOD1/RIPK2/p38/NF-κB signaling pathway. NOD1 knockdown reduces IL8 induction by >62%, while inhibitors of RIPK2, p38 or NF-κB can significantly suppress this response[1].
C12-iE-DAP (1 μg/mL) acts synergistically with LPS (5 ng/mL) for 6 h to enhance IL8 mRNA expression in primary human brain pericytes, and the induced level is higher than that of LPS (100 ng/mL) alone[1].
C12-iE-DAP (2,000 ng/mL) increases the adhesion of HT29 cells to fibronectin, collagen I and collagen IV by approximately 2-fold, 2-fold and 1.5-fold, respectively, enhances the migration of HT29 cells by approximately 2-fold, and simultaneously increases the adhesion of MC38 cells to both collagen I and fibronectin by approximately 1.5-fold[4].
C12-iE-DAP (up to 2,000 ng/mL; up to 80 min) increases p38 phosphorylation in colorectal cancer cells by up to approximately 7-fold in a dose- and time-dependent manner, but does not induce corresponding changes in IκBα degradation[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human monocytic THP-1 cells
-
Concentration:1-100 μg/mL
-
Incubation Time:24 h
-
Result:Induced IL-8 production in a dose-dependent manner.
Produced IL-8 production levels greater than the sum of levels induced by individual stimulation when combined with Curdlan or TDB, demonstrating a synergistic potentiation effect.
-
Cell Line:human monocytic THP-1 cells
-
Concentration:10 μg/mL
-
Incubation Time:24 h (agonist incubation); inhibitors added 1 h prior to agonist treatment
-
Result:Abrogated IL-8 production induced by individual treatment when RIP2 was inhibited via gefitinib.
Reduced IL-8 production induced by combined treatment with TDB to near baseline levels when RIP2 was inhibited via gefitinib.
Showed no significant effect on IL-8 production induced by individual treatment when Syk was inhibited via piceatannol.
Reduced IL-8 production induced by combined treatment with TDB to levels equivalent to individual treatment when Syk was inhibited via piceatannol.
Completely abrogated IL-8 production induced by both individual and combined treatment when dexamethasone was used.
-
Cell Line:human colorectal cancer HT29 cells
-
Concentration:2000 ng/mL
-
Incubation Time:60 min (following 30 min DMSO pre-incubation)
-
Result:Induced a 2-fold increase in HT29 cell migration compared to DMSO vehicle control, with statistical significance.
-
Cell Line:human colorectal cancer HT29 cells
-
Concentration:500-2000 ng/mL (fixed incubation time); 2000 ng/mL (time-dependent analysis)
-
Incubation Time:fixed time (dose-dependent analysis); 20-80 min (2000 ng/mL)
-
Result:Induced a dose-dependent increase in p38 phosphorylation, with up to a 7-fold increase at 2000 ng/mL compared to DMSO contro.
Induced a time-dependent increase in p38 phosphorylation, with up to a 2.3-fold increase at 80 min compared to baseline.
In Vivo
Activation of the NOD1 signaling pathway via C12-iE-DAP (1 mM; intracerebroventricular injection; once every 3 days for 4 weeks) abolishes the cognitive-improving, anti-inflammatory and anti-Aβ plaque effects of Avn-C in obese 5×FAD mice, with significant reversals observed in key indicators including the novel object recognition index, time spent in the target quadrant of the MWM, pro-inflammatory cytokine levels and Aβ load[3].
When MC38 cells pretreated with C12-iE-DAP (2,000 ng/mL) are injected intrasplenically into C57BL/6 mice, 37 metastatic nodules form on the liver surface on day 21[4].
Intrasplenic injection of HT29 or MC38 cells pretreated with C12-iE-DAP (2,000 ng/mL) increases their adhesion to liver sinusoids in C57BL/6 mice by approximately 2-fold, and this effect is blocked by ML130 (10 μM)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, SPF, 5-6 weeks old)[2]
-
Dosage:C12-iE-DAP: 1 μg/mouse; Curdlan; TDB: 10 μg/mouse
-
Administration:i.m.; single dose
-
Result:Co-stimulation synergistically increased serum IL-6 and KC levels at 3 h.
-
Animal Model:5×FAD (male, 2 months old, high-fat diet-induced obesity-accelerated Alzheimer's disease)[3]
-
Dosage:1 mM
-
Administration:i.c.v.; once every three days; 4 weeks
-
Result:Reduced object-recognition and spatial-memory performance.
Reversed the reductions in NOD1/RIP2/NF-κB signaling, inflammatory cytokines and Aβ deposition induced by Avenanthramide-C.
Chemical Information
-
CAS No. 1269619-57-9
-
Molecular Weight 501.61
-
Formula C24H43N3O8
-
Synonyms
Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid; γ-D-glutamyl-meso-diaminopimelic acid
-
Sequence
Lauroyl-γ-d-Glu-meso-diaminopimelic acid
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Extracell Vesicles
Tumour-Derived Extracellular Vesicles Reprogramme Tumour-Associated Macrophages Into Immunosuppressive Phenotype via NOD1 Signalling in Clear Cell Renal Cell Carcinoma. [Abstract]2026 Jun;15(6):e70317. PMID: 42226559
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
[1]. Navarro R, et al. Role of nucleotide-binding oligomerization domain 1 (NOD1) in pericyte-mediated vascular inflammation. Journal of cellular and molecular medicine. 2016 May;20(5):980-6. [Content Brief]
[2]. Tukhvatulin AI, et al. NOD1/2 and the C-Type Lectin Receptors Dectin-1 and Mincle Synergistically Enhance Proinflammatory Reactions Both In Vitro and In Vivo. Journal of inflammation research. 2020;13:357-368. [Content Brief]
[3]. Wang M, et al. Avenanthramide-C Mitigates High-Fat Diet-Accelerated Alzheimer's Pathologies via NOD1-Driven Neuroinflammation in 5×FAD Mice. Nutrients. 2025 Aug 19;17(16):2679. [Content Brief]
[4]. Jiang HY, et al. Activation of the pattern recognition receptor NOD1 augments colon cancer metastasis. Protein & cell. 2020 Mar;11(3):187-201. [Content Brief]
[5]. Agnihotri G, et al. Structure-activity relationships in nucleotide oligomerization domain 1 (Nod1) agonistic γ-glutamyldiaminopimelic acid derivatives. Journal of medicinal chemistry. 2011 Mar 10;54(5):1490-510. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)